摘要
抗逆转录病毒药物的多种组合显着改善了 HIV-1 感染的治疗。然而,终生治疗和耐药性仍然是一个悬而未决的问题,需要不断努力寻找新的抗病毒药物。
背景:逆转录酶相关核糖核酸酶 H (RNase H) 可水解 HIV 基因组以合成病毒 DNA。目前,还没有 RNase H 抑制剂 (RHI) 进入临床阶段。因此,RNase H 可以被定义为药物设计的一个有吸引力的目标。目的:尽管有大量关于 RNase H 结构域的信息,但具有高特异性和低细胞毒性的 RHI 的开发令人失望。然而,现在越来越明显的是,逆转录酶是一种高度通用的酶,经历了重大的结构改变以完成其催化作用,并且逆转录酶聚合酶和 RNase H 结构域之间存在密切的空间和时间相互作用。本综述总结了当前靶向 RNase H 的挑战,包括选择性抑制 RNase H 与聚合酶和/或 HIV-1 整合酶的挑战以及活性位点抑制剂的弱抗病毒活性,可能是由于底物屏障阻碍小分子到达目标网站。此外,重点关注药物化学领域的最新进展,这些进展导致在过去几年中将几种小分子鉴定为 RHI。
结论:RHIs可能是一类具有新作用机制的新型药物,对于治疗耐药性HIV毒株非常宝贵。
关键词: 核糖核酸酶 H、逆转录酶、金属酶、RNase H 抑制剂、药物设计、HIV-1、艾滋病、抗病毒。
Current Medicinal Chemistry
Title:Small-molecule Inhibitors of HIV-1 Reverse Transcriptase-Associated Ribonuclease H Function: Challenges and Recent Developments
Volume: 28 Issue: 30
关键词: 核糖核酸酶 H、逆转录酶、金属酶、RNase H 抑制剂、药物设计、HIV-1、艾滋病、抗病毒。
摘要:
Multiple combinations of antiretroviral drugs have remarkably improved the treatment of HIV-1 infection. However, life-long treatments and drug resistance are still an open issue that requires continuous efforts for the identification of novel antiviral drugs.
Background: The reverse transcriptase-associated ribonuclease H (RNase H) hydrolyzes the HIV genome to allow synthesizing viral DNA. Currently, no RNase H inhibitors (RHIs) have reached the clinical phase. Therefore, RNase H can be defined as an attractive target for drug design.
Objective: Despite the wealth of information available for RNase H domain, the development of RHIs with high specificity and low cellular toxicity has been disappointing. However, it is now becoming increasingly evident that reverse transcriptase is a highly versatile enzyme, undergoing major structural alterations to complete its catalysis, and that exists a close spatial and temporal interplay between reverse transcriptase polymerase and RNase H domains. This review sums up the present challenges in targeting RNase H encompassing the challenges in selectively inhibiting RNase H vs polymerase and/or HIV-1 integrase and the weak antiviral activity of active site inhibitors, probably for a substrate barrier that impedes small molecules to reach the targeted site. Moreover, the focus is given on the most recent progress in the field of medicinal chemistry that has led to the identification of several small molecules as RHIs in the last few years.
Conclusion: RHIs could be a new class of drugs with a novel mechanism of action highly precious for the treatment of resistant HIV strains.
Export Options
About this article
Cite this article as:
Small-molecule Inhibitors of HIV-1 Reverse Transcriptase-Associated Ribonuclease H Function: Challenges and Recent Developments, Current Medicinal Chemistry 2021; 28 (30) . https://dx.doi.org/10.2174/0929867328666210322164557
DOI https://dx.doi.org/10.2174/0929867328666210322164557 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements